HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases

被引：19

作者：

Zhang, Han ^{[1
]}

Ren, Guoping ^{[1
]}

Wang, Xiaoling ^{[1
]}

Zhao, Jing ^{[1
]}

Yao, Hongtian ^{[1
]}

Bai, Yanfeng ^{[1
]}

Bo, Wang ^{[1
]}

机构：

[1] Zhejiang Univ, Dept Pathol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2012年 / 134卷 / 02期

基金：

匈牙利科学研究基金会;

关键词：

Breast cancer; Fluorescence in situ hybridization; HER-2/neu; PROGESTERONE-RECEPTOR GENE; INTEROBSERVER REPRODUCIBILITY; PROTEIN OVEREXPRESSION; ESTROGEN; EXPRESSION; ANEUSOMY; TISSUE;

D O I：

10.1007/s10549-012-2101-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The concordance rate between fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) on evaluating HER-2/neu status is still controversial, especially for the IHC 2+/equivocal cases. In this study, we investigated the amplification of HER-2/neu gene by FISH in IHC (2+)/equivocal specimens to clarify the correlation between HER-2/neu and clinicopathologic features of breast cancers. HER-2/neu amplification was determined by FISH on 528 specimens of breast carcinomas with equivocal expression of HER-2/neu protein by IHC detection. 65.5 % of IHC 2+ patients were negative for HER-2/neu amplification, 29.0 % were positive and the remaining was equivocal. A statistically significant inverse association was found between hormone receptor expression and HER-2/neu amplification (P < 0.05). Furthermore, polysomy of CEP17 was detected in 60 % of breast carcinomas. The results highlight the necessity of FISH test for further categorization when breast carcinoma cases are scored 2+ by IHC.

引用

页码：743 / 749

页数：7

共 30 条

[21]

RUSSELL KS, 1992, CANCER RES, V52, P6624

[22] Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations [J].

Sauter, Guido ;

Lee, James ;

Bartlett, John M. S. ;

Slamon, Dennis J. ;

Press, Michael F. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1323-1333

[23] HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].

SLAMON, DJ ;

CLARK, GM ;

WONG, SG ;

LEVIN, WJ ;

ULLRICH, A ;

MCGUIRE, WL .

SCIENCE, 1987, 235 (4785) :177-182

[24]

Tsuda H, 2001, CANCER-AM CANCER SOC, V92, P2965, DOI 10.1002/1097-0142(20011215)92:12<2965::AID-CNCR10156>3.0.CO

[25]

2-A

[26] Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma [J].

Vang, R ;

Cooley, LD ;

Harrison, WR ;

Reese, T ;

Abrams, J .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (05) :669-674

[27] Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma [J].

Watters, AD ;

Going, JJ ;

Cooke, TG ;

Bartlett, JMS .

BREAST CANCER RESEARCH AND TREATMENT, 2003, 77 (02) :109-114

[28] American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J].

Wolff, Antonio C. ;

Hammond, M. Elizabeth H. ;

Schwartz, Jared N. ;

Hagerty, Karen L. ;

Allred, D. Craig ;

Cote, Richard J. ;

Dowsett, Mitchell ;

Fitzgibbons, Patrick L. ;

Hanna, Wedad M. ;

Langer, Amy ;

McShane, Lisa M. ;

Paik, Soonmyung ;

Pegram, Mark D. ;

Perez, Edith A. ;

Press, Michael F. ;

Rhodes, Anthony ;

Sturgeon, Catharine ;

Taube, Sheila E. ;

Tubbs, Raymond ;

Vance, Gail H. ;

de Vijver, Marc Van ;

Wheeler, Thomas M. ;

Hayes, Daniel F. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) :118-145

[29] HER-2 testing in breast cancer using parallel tissue-based methods [J].

Yaziji, H ;

Goldstein, LC ;

Barry, TS ;

Werling, R ;

Hwang, H ;

Ellis, GK ;

Gralow, JR ;

Livingston, RB ;

Gown, AM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (16) :1972-1977

[30]

Yosepovich A, 2010, ISR MED ASSOC J, V12, P353

← 1 2 3 →